The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin

Metabolism: Clinical and Experimental
Matthias KernMatthias Blüher

Abstract

Combining different drug classes to improve glycemic control is one treatment strategy for type 2 diabetes. The effects on insulin sensitivity of long-term treatment with the sodium glucose co-transporter 2 (SGLT2) inhibitor empagliflozin alone or co-administered with the dipeptidyl peptidase-4 inhibitor linagliptin (both approved antidiabetes drugs) were investigated in mice using euglycemic-hyperinsulinemic clamps. db/db mice (n=15/group) were treated for 8weeks with 10mg/kg/day empagliflozin monotherapy, 10mg/kg/day empagliflozin plus 3mg/kg/day linagliptin combination therapy, or 3mg/kg/day linagliptin monotherapy. At the end of the study, euglycemic-hyperinsulinemic clamp studies were performed 4days after the last dose of treatment. HbA1c and 2-hour fasting glucose concentrations were improved with empagliflozin monotherapy and combination therapy compared with vehicle and linagliptin monotherapy. During the clamp, glucose disposal rates increased and hepatic glucose production decreased with empagliflozin monotherapy and combination therapy compared with vehicle and linagliptin monotherapy. Glucose uptake in liver and kidney was higher with empagliflozin monotherapy and combination therapy compared with vehicle; glucose ...Continue Reading

References

May 1, 1987·The Journal of Clinical Investigation·L RossettiR A DeFronzo
Oct 22, 2003·Journal of the American Society of Nephrology : JASN·René SanterDan Klaerke
Nov 1, 1933·The Journal of Clinical Investigation·H ChasisH W Smith
Dec 2, 2009·Expert Opinion on Investigational Drugs·Carolyn F Deacon, Jens J Holst
Jan 21, 2010·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Stefan BlechKlaus Wagner
Aug 28, 2010·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Nirupa SachithanandanGregory R Steinberg
Mar 2, 2011·Diabetes·Ele Ferrannini
Mar 30, 2011·Drugs·Lesley J Scott
May 6, 2011·Journal of Clinical Pharmacology·Raktim Kumar GhoshSarfaraz Abdeli Jasdanwala
May 25, 2011·Endocrine Reviews·Muhammad A Abdul-GhaniRalph A Defronzo
Apr 25, 2012·Current Diabetes Reports·Muhammad A Abdul-GhaniRalph A DeFronzo
Jan 28, 2014·The Journal of Clinical Investigation·Aurora MerovciRalph A DeFronzo
Jan 28, 2014·The Journal of Clinical Investigation·Ele FerranniniHans-Juergen Woerle
May 23, 2014·The Journal of Pharmacology and Experimental Therapeutics·David R PowellZhi-Ming Ding

❮ Previous
Next ❯

Citations

Nov 12, 2016·International Journal of Environmental Research and Public Health·Sabine HergetSusann Blüher
Dec 27, 2016·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Yoshio SumidaUNKNOWN Japan Study Group of NAFLD (JSG-NAFLD)
Feb 14, 2017·British Journal of Pharmacology·Annika ÅstrandDeborah L Baines
Mar 17, 2017·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Atsushi Tanaka, Koichi Node
Oct 12, 2018·Proceedings of the National Academy of Sciences of the United States of America·Michael A van der KooijMarianne B Müller
Feb 6, 2020·Journal of Clinical Medicine·Teresa Caro-OrdieresJesús Egido
Oct 16, 2019·Endocrine, Metabolic & Immune Disorders Drug Targets·Habib YaribeygiAmirhossein Sahebkar
Mar 21, 2020·Journal of Diabetes Investigation·Ryuhei SanoTakeshi Ohta
May 6, 2019·Endocrine Reviews·Antonino Di Pino, Ralph A DeFronzo
Apr 7, 2020·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·Petra BaumJoanna Kosacka
Apr 9, 2020·Alzheimer's Research & Therapy·Carmen Hierro-BujalanceMonica Garcia-Alloza
Jun 11, 2018·Current Diabetes Reports·Dorrin Zarrin Khat, Mansoor Husain
Nov 18, 2018·Journal of Cellular Physiology·Habib YaribeygiAmirhossein Sahebkar
Aug 15, 2019·Heart Failure Reviews·Petra Grubić RotkvićLuka Rotkvić
Apr 10, 2019·Current Vascular Pharmacology·Vasilios G AthyrosChristos S Mantzoros
Oct 27, 2018·Expert Opinion on Drug Metabolism & Toxicology·Sempastian Filippas-NtekouanMoses Elisaf
Sep 10, 2019·European Journal of Pharmacology·Bhoomika M Patel, Ramesh K Goyal
Apr 20, 2021·Current Opinion in Lipidology·Julieta LazarteRobert A Hegele
Jun 16, 2021·Journal of Gastroenterology and Hepatology·Susrichit PhrueksotsaiSatawat Thongsawat
Aug 17, 2019·Molecular and Cellular Endocrinology·Tamiris Ingrid Petito-da-SilvaSandra Barbosa-da-Silva
Aug 28, 2021·Antioxidants·Kai-Fan TsaiChien-Te Lee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Asprosin

Asprosin is a fasting-induced hormone produced in the white adipose tissue to stimulate the hepatic release of glucose into the bloodstream. Discover the latest research on this protein hormone here.